What drugs does UNICHEM make?

UNICHEM has 68 FDA-approved drugs including IRBESARTAN AND HYDROCHLOROTHIAZIDE.

What therapeutic areas does UNICHEM focus on?

UNICHEM focuses primarily on Cardiovascular and Neurology and 1 other therapeutic areas.

← Back

Data updated: Sep 20, 2026

UNICHEM

Generics

Cardiovascular Neurology Gastroenterology

UNICHEM is a generic drug manufacturer focused on Cardiovascular, Neurology, Gastroenterology.

2006

Since

Drugs

Trials

New Drugs (2yr)

Modality:

1 Small Molecules

UNICHEM's Key Drugs

UNICHEM's core commercial portfolio centers on IRBESARTAN AND HYDROCHLOROTHIAZIDE, spanning Cardiovascular and Neurology — its most strategically important drugs approved in the last 15 years.

IRBESARTAN AND HYDROCHLOROTHIAZIDE

Cardiovascular

Approved 2012

UNICHEM's Recent FDA Approvals

UNICHEM secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

FAMOTIDINE NDA

2025-07-16

famotidine

1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.

UNICHEM's Therapeutic Areas

UNICHEM's approved drugs and pipeline span 4 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 57%

12 drugs

Neurology 29%

6 drugs

Gastroenterology 10%

2 drugs

Immunology 5%

1 drugs

UNICHEM's Top Competitors

UNICHEM's closest competitors by therapeutic-area and drug-target overlap include WARNER CHILCOTT, Bristol-Myers Squibb, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

WARNER CHILCOTT big-pharma

Cardiovascular, Gastroenterology, Neurology, Immunology

Bristol-Myers Squibb big-pharma

Immunology, Gastroenterology, Neurology

BAUSCH specialty

Immunology, Cardiovascular, Gastroenterology

Takeda big-pharma

Immunology, Gastroenterology, Cardiovascular

APOTHECON specialty

Cardiovascular, Gastroenterology, Immunology